_0001.png)
_0003.gif)
_0007.png)
_0006.gif)
_0005.png)
Consultants
_0025.png)
Dr. Michael Scolaro
Chief Medical Consultant
Chief Medical Consultant
Dr. Jörg Ruppert
Chief Consultant Business Development
Chief Consultant Business Development
Louis Capozzi, MBA
Chief Consultant
Public Relations
Chief Consultant
Public Relations
Dr. Robert Gieseler-von der Crone, Co-founder and CSO
Robert Gieseler is a biologist by training, specialized on Immunology as of 1985, and in 1991 received his PhD in Immunology focusing in basic research on human and rodent APCs. He was among those identifying the ontogeny of myeloid Dendritic Cells, and co-developed the key in-vitro differentiation protocol for these APCs. He joined Dr. Scolaro in 1990 and worked in a joint HIV/AIDS research program by St. Vincent Medical Center and the University of Southern California Medical School in Los Angeles, USA. Subsequently, he did commissioned work for the Merck Frosst Centre for Therapeutic Research in Quebec, Canada, and then led (pre)clinical research programs on solid organ transplantation, oncology, and autoimmunity at Georg August University, Göttingen, and the University Hospital of Essen, Germany. As of 2001, he worked for five years as Chief Scientist at a public non-profit research institute in Los Angeles together with Dr. Scolaro. With a team of scientists, their work provided the foundation for the proprietary technology developed at RBT. He also held a position as Adjunct Professor at the University of Florida, USA. Prior to founding RBT, he supervised the Northern Europe R&D division of a medium-sized European pharmaceutical company and served as Research Coordinator on hepatitis C and other liver diseases at the University Hospital of Essen, Germany.
Robert Gieseler is a biologist by training, specialized on Immunology as of 1985, and in 1991 received his PhD in Immunology focusing in basic research on human and rodent APCs. He was among those identifying the ontogeny of myeloid Dendritic Cells, and co-developed the key in-vitro differentiation protocol for these APCs. He joined Dr. Scolaro in 1990 and worked in a joint HIV/AIDS research program by St. Vincent Medical Center and the University of Southern California Medical School in Los Angeles, USA. Subsequently, he did commissioned work for the Merck Frosst Centre for Therapeutic Research in Quebec, Canada, and then led (pre)clinical research programs on solid organ transplantation, oncology, and autoimmunity at Georg August University, Göttingen, and the University Hospital of Essen, Germany. As of 2001, he worked for five years as Chief Scientist at a public non-profit research institute in Los Angeles together with Dr. Scolaro. With a team of scientists, their work provided the foundation for the proprietary technology developed at RBT. He also held a position as Adjunct Professor at the University of Florida, USA. Prior to founding RBT, he supervised the Northern Europe R&D division of a medium-sized European pharmaceutical company and served as Research Coordinator on hepatitis C and other liver diseases at the University Hospital of Essen, Germany.
- Home
- About us
- Research and Development
- Publications
- Partnerships
- Media
- FAQ
- Careers
- Contact
Dr. Michael Scolaro, Co-founder and Chief Medical Consultant
Physician (MD) by training with more than 40 years of experience in psychiatry, neurology, internal medicine, infectiology, and virology. His early clinical work and research contributed to the development of today’s state-of-the-art combination therapy for treatment of HIV/AIDS, i.e. HAART. As the founder and senior investigator of a public non-profit research institute in Los Angeles, USA - Let There Be Hope Medical Research Institute - and the former Director of AIDS Research at the St. Vincent Medical Center in Los Angeles, he was a principal investigator and contributor to over 40 clinical studies in HIV/AIDS, oncology and infectious diseases. In 1971, he was appointed to the position of Clinical Associate Professor at the University of Southern California. Los Angeles.
Physician (MD) by training with more than 40 years of experience in psychiatry, neurology, internal medicine, infectiology, and virology. His early clinical work and research contributed to the development of today’s state-of-the-art combination therapy for treatment of HIV/AIDS, i.e. HAART. As the founder and senior investigator of a public non-profit research institute in Los Angeles, USA - Let There Be Hope Medical Research Institute - and the former Director of AIDS Research at the St. Vincent Medical Center in Los Angeles, he was a principal investigator and contributor to over 40 clinical studies in HIV/AIDS, oncology and infectious diseases. In 1971, he was appointed to the position of Clinical Associate Professor at the University of Southern California. Los Angeles.
Dr. Jörg Ruppert, Co-founder and Chief Consultant Investor Relations
Biologist by training; received his PhD in Immunology in 1992. When at Georg August University in Göttingen, he co-developed the key in-vitro differentiation protocol for dendritic cells. In 1990, he joined Dr. Scolaro and contributed to the early investigations into therapeutic intracellular targeting of HIV-infected APCs with sense/antisense to the tat gene. Subsequently, Dr. Ruppert joined the publicly listed biotech company Cytel Corp. in San Diego, California, as a Research Scientist for three years in drug development utilizing antigen presentation technologies. After three years in a position in Marketing with the German subsidiary of a large US corporation, ICN Biomedicals, he became a partner for eight years with the Venture Capital firm, Heidelberg Innovation, as an Investment Manager specializing in financing, developing, and selling of biotechnology and pharmaceutical start-up companies. He currently holds the position of Director International Sales & Marketing with a medium-sized Diagnostics Company in Germany.
Biologist by training; received his PhD in Immunology in 1992. When at Georg August University in Göttingen, he co-developed the key in-vitro differentiation protocol for dendritic cells. In 1990, he joined Dr. Scolaro and contributed to the early investigations into therapeutic intracellular targeting of HIV-infected APCs with sense/antisense to the tat gene. Subsequently, Dr. Ruppert joined the publicly listed biotech company Cytel Corp. in San Diego, California, as a Research Scientist for three years in drug development utilizing antigen presentation technologies. After three years in a position in Marketing with the German subsidiary of a large US corporation, ICN Biomedicals, he became a partner for eight years with the Venture Capital firm, Heidelberg Innovation, as an Investment Manager specializing in financing, developing, and selling of biotechnology and pharmaceutical start-up companies. He currently holds the position of Director International Sales & Marketing with a medium-sized Diagnostics Company in Germany.
Louis Capozzi, Chief Consultant Public Relations
Louis Capozzi is a journalism graduate and holds an MBA in Finance. As a Financial Writer, he wrote dozens of corporate annual reports, acted as a speechwriter for CEOs and handled financial and investor communications from small firms to Fortune 50 global corporations. He then went to Hill & Knowlton, later joined Bankers Trust Company in New York managing communications for state-wide banking acquisitions, became Director of Communications and Investor Relations at AutEx, Inc., and headed the New York office of Ketchum Public Relations. As Vice President of Corporate Communications for Aetna Life & Casualty, he managed a 150-person corporate communications department budgeted at over US$ 80 million. During his time as Chairman and CEO of Manning, Selvage & Lee, the firm tripled in size, became one of the leaders in its field, and was named ‘Agency of the Year’ in 2003. Until 2006, he was Chairman of Publicis Public Relations and Corporate Communications Group, the world’s fourth-largest communications holding company, where he oversaw all of the group’s US$ 4-billion PR and corporate communications businesses. Currently, he serves as an Adjunct Professor in Public Relations and Corporate Communications at New York University. Louis Capozzi has extensive experience in crisis and issues management, such as for The American Medical Association, Upjohn, Hoffman La-Roche, Gillette, Philips, Nike, Westinghouse, the accounting industry and others. He frequently contributes to communications industry publications and acts as a spokesman for the industry in global media and as a speaker at industry events.
Louis Capozzi is a journalism graduate and holds an MBA in Finance. As a Financial Writer, he wrote dozens of corporate annual reports, acted as a speechwriter for CEOs and handled financial and investor communications from small firms to Fortune 50 global corporations. He then went to Hill & Knowlton, later joined Bankers Trust Company in New York managing communications for state-wide banking acquisitions, became Director of Communications and Investor Relations at AutEx, Inc., and headed the New York office of Ketchum Public Relations. As Vice President of Corporate Communications for Aetna Life & Casualty, he managed a 150-person corporate communications department budgeted at over US$ 80 million. During his time as Chairman and CEO of Manning, Selvage & Lee, the firm tripled in size, became one of the leaders in its field, and was named ‘Agency of the Year’ in 2003. Until 2006, he was Chairman of Publicis Public Relations and Corporate Communications Group, the world’s fourth-largest communications holding company, where he oversaw all of the group’s US$ 4-billion PR and corporate communications businesses. Currently, he serves as an Adjunct Professor in Public Relations and Corporate Communications at New York University. Louis Capozzi has extensive experience in crisis and issues management, such as for The American Medical Association, Upjohn, Hoffman La-Roche, Gillette, Philips, Nike, Westinghouse, the accounting industry and others. He frequently contributes to communications industry publications and acts as a spokesman for the industry in global media and as a speaker at industry events.